Home › Upcoming votes › Processa Pharmaceuticals, Inc.
The deadline as the proxy statement states it: “vote must be received by 11:59 p.m., Eastern Time, on November 29, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot: see the proxy statement. The items on this ballot could not be read from the filing with enough confidence to list them here. Read the proxy statement.
From Processa Pharmaceuticals, Inc.’s Form 8-K, filed September 12, 2025, for the meeting held September 11, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized s | 82% | — |
| 2. Approval of an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, | 82% | — |
| 3. Approval of an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shar | 80% | — |
| 4. Approval of an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if | 85% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the filing automatically and checked against the proxy’s own item count and voting card; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.